Long-term complete response in small cell bladder carcinoma treated with carboplatin, etoposide, and atezolizumab
Abstract Background Small cell bladder carcinoma (SCBC) is a rare and aggressive malignant tumor with no established treatment guidelines. Its treatment algorithm has been based on the small cell lung cancer (SCLC) guidelines. Metastatic SCBC has poor prognosis (even when treated with platinum-based...
| Main Authors: | , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
BMC
2022-11-01
|
| Series: | BMC Urology |
| Subjects: | |
| Online Access: | https://doi.org/10.1186/s12894-022-01130-4 |
| _version_ | 1811328874966941696 |
|---|---|
| author | Rei Kamitani Toshiyuki Ando Kazuya Hanai Arihito Tanaka Fumihiro Kashizaki Yasutomo Sekido Ryuichi Mizuno |
| author_facet | Rei Kamitani Toshiyuki Ando Kazuya Hanai Arihito Tanaka Fumihiro Kashizaki Yasutomo Sekido Ryuichi Mizuno |
| author_sort | Rei Kamitani |
| collection | DOAJ |
| description | Abstract Background Small cell bladder carcinoma (SCBC) is a rare and aggressive malignant tumor with no established treatment guidelines. Its treatment algorithm has been based on the small cell lung cancer (SCLC) guidelines. Metastatic SCBC has poor prognosis (even when treated with platinum-based chemotherapy, which is usually used for extensive-disease SCLC). Case presentation Herein, we report a case of a 71-year-old man with SCBC who underwent radical cystectomy and received adjuvant chemotherapy with gemcitabine and cisplatin. However, recurrent tumors were found 6 months postoperatively. The patient was then treated with carboplatin, etoposide, and atezolizumab and achieved complete response. He continues receiving maintenance therapy with atezolizumab monotherapy without any evidence of recurrence over the 12 months follow up. Conclusion To our knowledge, this is the first case of metastatic SCBC where carboplatin, etoposide, and atezolizumab achieved long-term complete response. |
| first_indexed | 2024-04-13T15:33:52Z |
| format | Article |
| id | doaj.art-fdd29d19c9ba43e0ae9f6c45b74d1275 |
| institution | Directory Open Access Journal |
| issn | 1471-2490 |
| language | English |
| last_indexed | 2024-04-13T15:33:52Z |
| publishDate | 2022-11-01 |
| publisher | BMC |
| record_format | Article |
| series | BMC Urology |
| spelling | doaj.art-fdd29d19c9ba43e0ae9f6c45b74d12752022-12-22T02:41:20ZengBMCBMC Urology1471-24902022-11-012211510.1186/s12894-022-01130-4Long-term complete response in small cell bladder carcinoma treated with carboplatin, etoposide, and atezolizumabRei Kamitani0Toshiyuki Ando1Kazuya Hanai2Arihito Tanaka3Fumihiro Kashizaki4Yasutomo Sekido5Ryuichi Mizuno6Department of Urology, Isehara Kyodo HospitalDepartment of Urology, Isehara Kyodo HospitalDepartment of Urology, Isehara Kyodo HospitalDepartment of Respiratory Medicine, Isehara Kyodo HospitalDepartment of Respiratory Medicine, Isehara Kyodo HospitalDepartment of Pathology, Isehara Kyodo HospitalDepartment of Urology, Keio University School of MedicineAbstract Background Small cell bladder carcinoma (SCBC) is a rare and aggressive malignant tumor with no established treatment guidelines. Its treatment algorithm has been based on the small cell lung cancer (SCLC) guidelines. Metastatic SCBC has poor prognosis (even when treated with platinum-based chemotherapy, which is usually used for extensive-disease SCLC). Case presentation Herein, we report a case of a 71-year-old man with SCBC who underwent radical cystectomy and received adjuvant chemotherapy with gemcitabine and cisplatin. However, recurrent tumors were found 6 months postoperatively. The patient was then treated with carboplatin, etoposide, and atezolizumab and achieved complete response. He continues receiving maintenance therapy with atezolizumab monotherapy without any evidence of recurrence over the 12 months follow up. Conclusion To our knowledge, this is the first case of metastatic SCBC where carboplatin, etoposide, and atezolizumab achieved long-term complete response.https://doi.org/10.1186/s12894-022-01130-4Small cell carcinomaBladder cancerAtezolizumabComplete responseCase report |
| spellingShingle | Rei Kamitani Toshiyuki Ando Kazuya Hanai Arihito Tanaka Fumihiro Kashizaki Yasutomo Sekido Ryuichi Mizuno Long-term complete response in small cell bladder carcinoma treated with carboplatin, etoposide, and atezolizumab BMC Urology Small cell carcinoma Bladder cancer Atezolizumab Complete response Case report |
| title | Long-term complete response in small cell bladder carcinoma treated with carboplatin, etoposide, and atezolizumab |
| title_full | Long-term complete response in small cell bladder carcinoma treated with carboplatin, etoposide, and atezolizumab |
| title_fullStr | Long-term complete response in small cell bladder carcinoma treated with carboplatin, etoposide, and atezolizumab |
| title_full_unstemmed | Long-term complete response in small cell bladder carcinoma treated with carboplatin, etoposide, and atezolizumab |
| title_short | Long-term complete response in small cell bladder carcinoma treated with carboplatin, etoposide, and atezolizumab |
| title_sort | long term complete response in small cell bladder carcinoma treated with carboplatin etoposide and atezolizumab |
| topic | Small cell carcinoma Bladder cancer Atezolizumab Complete response Case report |
| url | https://doi.org/10.1186/s12894-022-01130-4 |
| work_keys_str_mv | AT reikamitani longtermcompleteresponseinsmallcellbladdercarcinomatreatedwithcarboplatinetoposideandatezolizumab AT toshiyukiando longtermcompleteresponseinsmallcellbladdercarcinomatreatedwithcarboplatinetoposideandatezolizumab AT kazuyahanai longtermcompleteresponseinsmallcellbladdercarcinomatreatedwithcarboplatinetoposideandatezolizumab AT arihitotanaka longtermcompleteresponseinsmallcellbladdercarcinomatreatedwithcarboplatinetoposideandatezolizumab AT fumihirokashizaki longtermcompleteresponseinsmallcellbladdercarcinomatreatedwithcarboplatinetoposideandatezolizumab AT yasutomosekido longtermcompleteresponseinsmallcellbladdercarcinomatreatedwithcarboplatinetoposideandatezolizumab AT ryuichimizuno longtermcompleteresponseinsmallcellbladdercarcinomatreatedwithcarboplatinetoposideandatezolizumab |